This research report on the global cell and gene therapy market covers sizing and forecast, share, industry trends, growth drivers, and vendor analysis. The study includes insights by products (Cell therapy and gene therapy), application (oncology, dermatology, musculoskeletal, and others), End-Users (hospitals, wound care centers, cancer care centers, ambulatory surgical centers, and others), and geography (North America, APAC, Europe, Latin America, and MEA).
The major drivers contributing to the growth of the global cell and gene therapy market are the growing incidence of several chronic and terminal diseases, including cancer, the launch of new products, the increasing availability in clinical evidences of these products in terms of safety and efficacy, the rapid adoption of CAR T-cell therapy, favorable regulatory support in the development of these treatment, and improved manufacturing expertise in these products.
The combination of cell and gene therapy products with other treatment method is a significant trend, which is catching pace in the market. Several clinical studies are highlighting the efficacy of cancer management when these products are combined with monoclonal antibodies-based molecules (immune checkpoint inhibitors) and traditional chemotherapy. Hence, their expanding application is expected to boost the market during the forecast period. Several cell and gene therapy products are receiving regulatory approvals faster than other products due to their superior safety and efficacy profiles for treating many diseases such as cancer, acute and chronic wounds, genetic diseases, blindness, and musculoskeletal deformities, as well as incurable/difficult to treat conditions.
The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018–2024.
This research report includes detailed market segmentation by product, application, end-user, and geography.
The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments. The segment is likely to witness upward growth on account of expanded expertise in the manufacturing of stem cell-based products.
The gene therapy segment is expected to witness faster growth as the penetration of these products is increasing at a significant rate, especially in developed economies. The market is expected to grow during the forecast period due to the increased patient base for the existing gene remedy products, expected the launch of other gene therapy-based products for several indications, and expanded indication approvals for existing commercially available products.
The oncology segment accounts for the highest share of the global market. The growth of the oncology segment is increasing at a fast rate on account of the growing prevalence of several types of cancers. Currently, the available products not only modify the disease but also improve the quality of the patient’s life, thereby decreasing the mortality rate.
The market in the dermatology segment is increasing at a steady rate. This segment owns its growth to the increasing incidence and prevalence rate of several types of wounds, which are difficult to treat under normal conditions and the launch of innovative products. The dermatology segment is likely to showcase growth due to the high product availability of wound care products in the market.
Hospitals are the leading end-user segment. The segment is growing mainly due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic wound on account of diabetes feet, pressure ulcers, and other injuries.
The cancer care centers end-user segment is likely to grow on account of the prevalence of cancers across the world, the need for a special treatment approach for cancer management, increased R&D focus on investigational remedy, and the availability of super-specialty expertise in the treatment at care centers.
The US market dominates the cell and gene therapy market in North America due to the high prevalence of chronic diseases and other conditions, which require these treatment methods. There is also comparably high utilization and wide accessibility of these therapies. The oncology segment is likely to witness significant growth in North America.
The market in Europe is expected to witness upward growth in the near future on account of the growing prevalence of chronic diseases and rising elderly population. In Europe, cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally.
The APAC region is the third-largest market for cell and gene therapy products in the world. The major factors leading to the growth in APAC region are the growing prevalence of cancers, osteoarthritis, burns, and other chronic wounds, the introduction of advanced products in Japan, advanced R&D activities in countries such as South Korea, India.
Key Vendor Analysis
The global market is characterized by the presence of a few global, large-scale companies and several small to medium-scale companies offering one or two cell and gene therapy products. Global players are majorly offering innovative products with the potential of disease-modifying characteristics that are generating significant revenues, especially in Europe and US regions. Most innovative and breakthrough products are approved in the European countries and the US. Vendors are targeting mostly developed economies such as the US, Germany, France, the UK, Spain, and Japan as the uptake of these products is higher in these countries than low and middle-income countries. However, the market in these regions is at the nascent stage.
Other Prominent Vendors – Anterogen, Tego Sciences, Japan Tissue Engineering, JCR Pharmaceuticals, Medipost, MolMed, AVITA Medical, CollPlant, Corestem, Biosolution, Stempeutics Research, Orchard Therapeutics, Takeda Pharmaceutical Company, CHIESI Farmaceutici, CO.DON, AnGes, GC Pharma, JW CreaGene, APAC Biotech, Nipro Corp., Terumo, Orthocell, and bluebird bio.
Key Market Insights
The report provides the following insights into the market for the forecast period 2019–2024.
Get the updated report free if published within 100 days of purchase
Free datasheet worth $1500 with team and corporate license.
10% free customization. Speak to our analyst